Literature DB >> 26586424

FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1.

Michelle M Kwon1, Shannon M O'Dwyer1, Robert K Baker1, Scott D Covey2, Timothy J Kieffer3.   

Abstract

Fibroblast growth factor 21 (FGF21)-mediated weight loss and improvements in glucose metabolism correlate with increased uncoupling protein 1 (Ucp1) levels in adipose tissues, suggesting that UCP1-dependent thermogenesis may drive FGF21 action. It was reported that FGF21 is equally effective at reducing body weight and improving glucose homeostasis without UCP1. We find while FGF21 can lower body weight in both wild-type and Ucp1 knockout mice, rapid clearance of glucose by FGF21 is defective in the absence of UCP1. Furthermore, in obese wild-type mice there is a fall in brown adipose tissue (BAT) temperature during glucose excursion, and FGF21 improves glucose clearance while preventing the fall in BAT temperature. In Ucp1 knockout mice, the fall in BAT temperature during glucose excursion and FGF21-mediated changes in BAT temperature are lost. We conclude FGF21-mediated improvements in clearance of a glucose challenge require UCP1 and evoke UCP1-dependent thermogenesis as a method to increase glucose disposal.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26586424     DOI: 10.1016/j.celrep.2015.10.021

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  27 in total

Review 1.  Emerging Complexities in Adipocyte Origins and Identity.

Authors:  Joan Sanchez-Gurmaches; Chien-Min Hung; David A Guertin
Journal:  Trends Cell Biol       Date:  2016-02-11       Impact factor: 20.808

Review 2.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

3.  Thermoneutrality but Not UCP1 Deficiency Suppresses Monocyte Mobilization Into Blood.

Authors:  Jesse W Williams; Andrew Elvington; Stoyan Ivanov; Skyler Kessler; Hannah Luehmann; Osamu Baba; Brian T Saunders; Ki-Wook Kim; Michael W Johnson; Clarissa S Craft; Jae-Hoon Choi; Mary G Sorci-Thomas; Bernd H Zinselmeyer; Jonathan R Brestoff; Yongjian Liu; Gwendalyn J Randolph
Journal:  Circ Res       Date:  2017-07-10       Impact factor: 17.367

Review 4.  A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21.

Authors:  Steven A Kliewer; David J Mangelsdorf
Journal:  Cell Metab       Date:  2019-02-05       Impact factor: 27.287

Review 5.  The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.

Authors:  Leiluo Geng; Karen S L Lam; Aimin Xu
Journal:  Nat Rev Endocrinol       Date:  2020-08-06       Impact factor: 43.330

Review 6.  Metabolic Messengers: FGF21.

Authors:  Kyle H Flippo; Matthew J Potthoff
Journal:  Nat Metab       Date:  2021-03-18

Review 7.  Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.

Authors:  Christoffer Clemmensen; Brian Finan; Timo D Müller; Richard D DiMarchi; Matthias H Tschöp; Susanna M Hofmann
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

8.  Fibroblast Growth Factor 21 Mediates Glycemic Regulation by Hepatic JNK.

Authors:  Santiago Vernia; Julie Cavanagh-Kyros; Tamera Barrett; Cathy Tournier; Roger J Davis
Journal:  Cell Rep       Date:  2016-03-03       Impact factor: 9.423

Review 9.  Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies.

Authors:  Shuang Hua; Qianying Liu; Jufei Li; Mengqi Fan; Kaixuan Yan; Dewei Ye
Journal:  Rev Endocr Metab Disord       Date:  2021-06-13       Impact factor: 6.514

Review 10.  Circulating α-klotho regulates metabolism via distinct central and peripheral mechanisms.

Authors:  Taylor Landry; Daniel Shookster; Hu Huang
Journal:  Metabolism       Date:  2021-06-19       Impact factor: 13.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.